

## ENZYMIC SYNTHESIS OF ETHANOLAMINE PLASMALOGENS FROM AN *O*-ALKYL GLYCEROLIPID

M.L. BLANK, Robert L. WYKLE and Fred SNYDER

Medical Division, Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, Tenn. 37830, USA

Received 16 August 1971

### 1. Introduction

*In vivo* studies directed toward the elucidation of plasmalogen biosynthesis have indicated that *O*-alkyl lipids can serve as precursors of *O*-alk-1-enyl lipids [1–7]. Our work with an enzymic system from neoplastic cells that synthesizes plasmalogens [8, 9] also supported this concept. (a) The substrate (hexadecanol and dihydroxyacetone-P) and cofactor requirements (CoA, ATP, and  $Mg^{2+}$ ) were identical for both types of ethers, except for the need of  $NADP^+$  (or  $NAD^+$ ) in plasmalogen synthesis, and (b) the  $^3H/^{14}C$  isotope ratios of the *O*-alkylglycerols and *O*-alk-1-enyl-glycerols derived from the products synthesized from 9,10- $^3H$ -hexadecanol and uniformly  $^{14}C$ -labeled dihydroxyacetone-P were identical. However, it was not possible for us completely to rule out other reactions that could account for the synthesis of the *O*-alk-1-enyl moiety, since a suitable substrate containing the *O*-alkyl bond was not available in the earlier studies.

We have now prepared and tested 1-(9,10- $^3H$ -alkyl)-2-acyl-(U) $^{14}C$ -glycerol-3-P as a potential precursor of plasmalogens in the enzymic system. Using this precursor, the CoA requirement was not essential, whereas  $NADP^+$  was still required for the conversion of the substrate to ethanolamine plasmalogens. The data demonstrate that the *O*-alkyl moiety is transformed to an *O*-alk-1-enyl moiety without cleavage of the ether bond and that the  $NADP^+$  requirement is two-fold: (a) It not only serves to generate  $NADPH^*$  which was necessary for reduction of the ketone group of *O*-alkyldihydroxyacetone-P as shown in our earlier

work [8–12] but, as shown here, (b) it is also involved as a cofactor in the formation of the *O*-alk-1-enyl bond.

### 2. Methods

Unless otherwise stated, the methodology, materials, and enzyme source used were identical to those previously described in detail [8–12]. The 1-(9,10- $^3H$ -alkyl)-2-acyl-(U) $^{14}C$ -glycerol-3-P was prepared from (U) $^{14}C$ -D-fructose-1,6-diphosphate (190 mCi/mmmole) and 9,10- $^3H$ -hexadecanol (400 mCi/mmmole) and isolated as before [12]; the preparation contained no radioactivity in *O*-alk-1-enyl lipids as determined by radioassay of dimethylacetals and *O*-alk-1-enylglycerols. 1-(1- $^{14}C$ -alkyl)-2-acylglycerol-3-P was prepared in the same manner from 1- $^{14}C$ -hexadecanol (46 mCi/mmmole) and unlabeled dihydroxyacetone-P. The legend of table 1 lists the components, concentrations, and conditions used for each incubation.

### 3. Results and discussion

The data in table 1 demonstrate that 1-(1- $^{14}C$ -alkyl)-2-acylglycerol-3-P serves as an effective precursor of ethanolamine plasmalogens (1-alk-1-enyl-2-acylglycerol-3-phosphorylethanolamine) when this precursor is incubated with a postmitochondrial fraction of Ehrlich ascites cells,  $NADP^+$ , CDP-ethanolamine, ATP, and  $Mg^{2+}$ ; coenzyme A was not essential. Plasmalogens were not synthesized from the alkyl analog of phosphatidic acid in the absence of  $NADP^+$ .

When the doubly labeled alkyl analog of phos-

\* Unpublished observation.

Table 1

The biosynthesis of ethanolamine plasmalogens from 1-(1-<sup>14</sup>C-alkyl)2-acylglycerol-3-P by a postmitochondrial fraction of Ehrlich ascites cells.

System	<sup>14</sup> C in total ethanolamine phospholipid fraction (%)	<sup>14</sup> C in ethanolamine plasmalogens (%)
1 Complete	10.1	9.24
2 Complete minus NADP <sup>+</sup>	7.28	0.71
3 Complete minus CoA	8.56	6.95

<sup>a</sup> The complete system contained the <sup>14</sup>C-substrate, ATP (10 mM), CoA (100 μM), Mg<sup>2+</sup> (4 mM), CDP-ethanolamine (1 mM), NADP<sup>+</sup> (2 mM), and postmitochondrial fraction (30 mg protein) in a final volume of 3 ml Tris buffer (0.1 M, pH 7.1). The 1-(1-<sup>14</sup>C-alkyl)2-acylglycerol-3-P (145,600 dpm per vial) was added to the system in 10 μl of 95% ethanol. Incubations were carried out at 37° for 90 min.

phatidic acid was used as a substrate, the <sup>3</sup>H and <sup>14</sup>C were incorporated into alkylacylglycerylphosphoryl-ethanolamine and alk-1-enylacylglycerylphosphoryl-ethanolamine in essentially the same ratios present in the precursor (table 2). The dimethylacetals of the aldehydes liberated from the *O*-alk-1-enyl moiety contained only <sup>3</sup>H, as expected from the location of <sup>14</sup>C and <sup>3</sup>H in the ether-linked precursor. Additional evidence that indicated the *O*-alkyl linkage was not cleaved is that > 98.5% of the <sup>3</sup>H was still associated with either the *O*-alkyl or *O*-alk-1-enyl glycerolipids after a 90-min incubation (table 2), i.e., only 1.5% of the activity could be isolated as fatty alcohols (derived from acyl moieties) after reduction with NaAlH<sub>2</sub>(OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>)<sub>2</sub>. The lack of *O*-alkyl cleavage enzymes in Ehrlich ascites cells has previously been established [13].

Our findings indicate that the *O*-alkyl moiety can indeed be transformed to an *O*-alk-1-enyl linkage, presumably via a dehydrogenation mechanism involving NADP<sup>+</sup> as a cofactor. The nature of this mechanism remains unknown, although *in vivo* experiments [2] have suggested that a rather complex substitution reaction(s) might be responsible. The experiments reported in this communication do not answer the question of which *O*-alkyl glycerolipid serves as the direct precursor of plasmalogens, but stimulation of ethanolamine plasmalogen synthesis by CDP-ethanol-

Table 2

Incorporation of 1-(9,10-<sup>3</sup>H-alkyl)-2-acyl-(U)<sup>14</sup>C-glycerol-3-P into ether-linked ethanolamine phospholipids<sup>a</sup>.

Sample	<sup>3</sup> H/ <sup>14</sup> C ratio
1 Substrate (alkylacylglycerol-P)	24
2 Alkylglycerols from ethanolamine phospholipids after reduction	23
3 Alk-1-enylglycerols <sup>b</sup> from ethanolamine phospholipids after reduction	22

<sup>a</sup> The complete incubation system was identical to that described in the legend of table 1 except that the 1-(9,10-<sup>3</sup>H-alkyl)-2-acyl-(U)<sup>14</sup>C-glycerol-3-P (1.6 × 10<sup>6</sup> dpm <sup>3</sup>H per vial), serving as substrate, was added in 10 μl diethyl ether: 95% ethanol, 2:1 (v/v). Under these conditions, 8% (based on <sup>3</sup>H assay) of the substrate was incorporated into the ethanolamine phospholipids and 11.6% of this activity was in the plasmalogen fraction; the alkyl ethanolamine phospholipids contained 86.8% of the <sup>3</sup>H. The products from five vials were pooled to obtain the data for samples (2) and (3). Reduction of the samples was accomplished with NaAlH<sub>2</sub>(OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>)<sub>2</sub>.

<sup>b</sup> The dimethylacetals of the aldehydes liberated by methanolic HCl contained only <sup>3</sup>H.

amine [14] suggests that the transformation occurs directly on alkylacylglycerylphosphorylethanolamine.

### Acknowledgements

This work was supported in part by Grant No. E-596B from the American Cancer Society, Grant No. CA11949.02 from the National Institutes of Health, and the U.S. Atomic Energy Commission.

### References

- [1] G.A. Thompson, Jr., *Biochim. Biophys. Acta* 152 (1968) 409.
- [2] M.L. Blank, R.L. Wykle, C. Piantadosi and F. Snyder, *Biochim. Biophys. Acta* 210 (1970) 442.
- [3] W. Stoffel, D. LeKim and G. Heyn, *Z. Physiol. Chem.* 351 (1970) 875.
- [4] R. Wood and K. Healy, *J. Biol. Chem.* 245 (1970) 2640.
- [5] W. Stoffel and D. LeKim, *Z. Physiol. Chem.* 352 (1971) 501.
- [6] O.E. Bell, Jr., M.L. Blank and F. Snyder, *Biochim. Biophys. Acta* 231 (1971) 579.

- [7] F. Paltauf, *Biochim. Biophys. Acta* 239 (1971) 38.
- [8] R.L. Wykle, M.L. Blank and F. Snyder, *FEBS Letters* 12 (1970) 57.
- [9] F. Snyder, M.L. Blank and R.L. Wykle, *J. Biol. Chem.* 246 (1971) 3639.
- [10] F. Snyder, B. Malone and M.L. Blank, *J. Biol. Chem.* 245 (1970) 1790.
- [11] F. Snyder, M.L. Blank, B. Malone and R.L. Wykle, *J. Biol. Chem.* 245 (1970) 1800.
- [12] R.L. Wykle and F. Snyder, *J. Biol. Chem.* 245 (1970) 3047.
- [13] J.F. Soodma, C. Piantadosi and F. Snyder, *Cancer Res.* 30 (1970) 309.
- [14] R.L. Wykle, M.L. Blank and F. Snyder, *Federation Proc.* 30 (1971) 1243.